Development of taste disorders following FOLFOX-FOLFIRI therapy and its effects on the QOL of patients with colorectal cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 36, Issue 3, 2009, Pages 431-435

  Takimoto, Norio ^a   Sugawara, Shiho ^a   Iida, Akiko ^a   Sakakibara, Takashi ^a   Mori, Kenji ^a   Sugiura, Mitsuru ^a   Yamamura, Keiko ^b   Adachi, Mamoru ^a  

^a Toyota Kai Medical Corporation Kariya Toyota General Hospital   (Japan)

^b AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

FOLFIRI; FOLFOX; Quality of life; Taste disorder

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; APPETITE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; DETERIORATION; HUMAN; NUTRITIONAL STATUS; QUALITY OF LIFE; RISK FACTOR; TASTE DISORDER;

EID: 79959832517     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1):23-30, 2004. (Pubitemid 41095110)
2. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938-2947, 2000. (Pubitemid 30644117)
3. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229-237, 2004. (Pubitemid 41095086)
4. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12):1539-1544, 2007. (Pubitemid 46733080)
5. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342, 2004. (Pubitemid 38702844)
6. Kabbinavar FF, Hambleton J, Mass RD, et al: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23(16):3706-3712, 2005.
7. Kurihara M, Shimizu H, Tsuboi K, et al: Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psychooncology 8(4):355-363, 1999. (Pubitemid 29417490)
8. Holmes S: Food avoidance in patients undergoing cancer chemotherapy. Support Care Cancer 1(6):326-330, 1993.
9. Hutton JL, Baracos VE and Wismer WV: Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer. J Pain Symptom Manage 33(2):156-165, 2007.
10. Dewys WD, Begg C, Lavin PT, et al: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69(4):491-497, 1980. (Pubitemid 10018703)
11. Tomita H and Yoshikawa T: Drug-related taste disturbances. Acta Otolaryngol Suppl 546:116-121, 2002.